8-K: Revance Therapeutics Announces Positive 2023 Results and Strategic 2024 Outlook

Revance Therapeutics reported strong year-over-year revenue growth for 2023, driven by increased sales of DAXXIFY and the RHA Collection, and provided a positive outlook for 2024.

Summary

• Revance Therapeutics reported a 77% increase in total revenue for 2023, reaching $234 million, compared to $132.6 million in 2022.
• Product revenue for 2023 was $212.7 million, an 80% increase year-over-year, with DAXXIFY contributing $84 million and the RHA Collection contributing $128.6 million.
• Fourth quarter 2023 product revenue was $58.5 million, a 28% increase year-over-year, with DAXXIFY revenue at $24 million and RHA Collection revenue at $34.5 million.
• The company's 2024 product revenue guidance is at least $280 million, indicating continued growth expectations.
• Revance anticipates achieving positive Adjusted EBITDA in 2025.
• Operating expenses for 2023 were $550.8 million, with a non-GAAP OPEX of $318.9 million, both at the low end of previous guidance.
• 2024 GAAP operating expenses are projected to be between $460 million and $490 million, and non-GAAP operating expenses between $290 million and $310 million.
• The company had $253.9 million in cash, cash equivalents, and short-term investments as of December 31, 2023.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, successful product launches, and a clear path to profitability. The company's strategic initiatives and positive market reception of its products contribute to this optimistic outlook. However, the net losses and adjusted EBITDA losses temper the sentiment slightly.

Positives

• Strong revenue growth in 2023, driven by both DAXXIFY and RHA Collection.
• Significant increase in DAXXIFY sales volume and reordering accounts.
• RHA Collection is the fastest-growing filler in the U.S. market.
• Successful expansion of DAXXIFY coverage with major payers.
• Positive feedback from physicians and patients in the DAXXIFY cervical dystonia PrevU program.
• Receipt of a permanent J-Code for DAXXIFY, facilitating reimbursement.
• Anticipated launch of DAXXIFY for cervical dystonia in mid-2024.
• Projected positive Adjusted EBITDA in 2025.
• Cost savings expected from exiting the OPUL payments business.
• Label expansion for RHA 3 to include lip augmentation.

Negatives

• The company reported a net loss of $324 million for the full year 2023.
• The company reported a net loss of $55.7 million for the fourth quarter of 2023.
• The company's adjusted EBITDA was a loss of $160.1 million for the full year 2023.
• The company's adjusted EBITDA was a loss of $42.6 million for the fourth quarter of 2023.
• The average selling price of DAXXIFY decreased in Q4 2023 due to a new pricing strategy.

Risks

• The company's ability to obtain funding for operations is a risk.
• The accuracy of estimates regarding expenses, revenues, and capital requirements is a risk.
• The company's financial performance and the economics of DAXXIFY and the RHA Collection are subject to risk.
• The company's ability to comply with debt obligations is a risk.
• Macroeconomic factors could impact manufacturing, supply chain, and demand for products.
• The company's ability to maintain product approvals is a risk.
• The company's ability to manufacture supplies for DAXXIFY and acquire supplies of the RHA Collection is a risk.
• The clinical development process is uncertain.
• The company's ability to obtain regulatory approvals is a risk.
• The commercial acceptance and market competition for DAXXIFY and the RHA Collection are risks.
• The company's ability to successfully commercialize DAXXIFY is a risk.
• The company's ability to secure adequate reimbursement for DAXXIFY is a risk.
• The company's ability to maintain intellectual property protection is a risk.
• The company is subject to product liability, intellectual property, and other lawsuits.
• The company is subject to cybersecurity risks.
• The company's stock price is volatile.

Future Outlook

Revance anticipates achieving positive Adjusted EBITDA in 2025 and expects continued growth in product revenue, driven by DAXXIFY and the RHA Collection, with a 2024 product revenue guidance of at least $280 million. The company also sees significant potential in the therapeutics market and international expansion.

Management Comments

• Mark J. Foley, Chief Executive Officer, stated that the company is well-positioned to execute on its strategic priorities and achieve its product revenue guidance of at least $280 million in 2024.
• Foley also noted the continued growth in DAXXIFY sales volumes and the RHA Collection's position as the fastest-growing filler in the market.
• Foley expressed excitement about the launch of DAXXIFY for cervical dystonia and the positive feedback from the PrevU program.
• Foley highlighted the company's focused investments and disciplined expense management to support corporate objectives and achieve positive Adjusted EBITDA in 2025.

Industry Context

Revance's performance is set against a backdrop of a growing aesthetics market, with increasing demand for both neuromodulators and dermal fillers. The company's focus on long-duration products and strategic partnerships positions it to compete effectively with established players in the market. The expansion into therapeutics with DAXXIFY for cervical dystonia also opens up a new market opportunity for the company.

Comparison to Industry Standards

• Revance's DAXXIFY launch has surpassed the combined sales of the last three neuromodulators to enter the market in their respective launch periods, indicating a strong initial market reception.
• The RHA Collection's position as the fastest-growing filler by market share demonstrates its competitive edge against other brands like Allergan's Juvederm and Galderma's Restylane.
• The company's focus on long-duration products aligns with a growing trend in the aesthetics market, where patients seek longer-lasting results.
• The company's strategic partnerships with Fosun and Viatris are similar to other biotech companies that leverage partnerships for international expansion and product development, such as AbbVie's partnership with Allergan.

Management Changes

Stakeholder Impact

• Shareholders: The positive financial results and future outlook are likely to be viewed favorably by shareholders.
• Employees: The restructuring and changes in management may impact employees, but the company's growth prospects could provide opportunities.
• Customers: The launch of new products and indications will provide more options for customers.
• Suppliers: The company's growth will likely lead to increased demand for supplies.
• Creditors: The company's improved financial position may reduce credit risk.

Next Steps

• Complete the DAXXIFY cervical dystonia PrevU program.
• Launch DAXXIFY for cervical dystonia mid-year 2024.
• Continue to grow DAXXIFY and RHA Collection market share.
• Expand the RHA Collection with new indications and products.
• Exit the OPUL payments business by the end of Q1 2024.
• Strengthen provider partnerships through engagement initiatives.
• Continue to focus on disciplined expense management and capital allocation.

Key Dates

Keywords

DAXXIFY, RHA Collection, Aesthetics, Cervical Dystonia, Botulinum Toxin, Dermal Fillers, Revenue Growth, Financial Results, Commercial Launch, Therapeutics, Adjusted EBITDA, Operating Expenses